发布求助
文献互助 智能选刊 最新文献

C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD最新文献

筛选
英文 中文
Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in Patients With COPD: Results From Replicate Phase 3 Trials Ensifentrine，一种新型双磷酸二酯酶(PDE) 3和4抑制剂，改善COPD患者的肺功能，症状，生活质量，降低加重率和风险:来自重复3期试验的结果
C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5005
F. Sciurba, A. Anzueto, T. Rheault, T. Bengtsson, K. Rickard
{"title":"Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in Patients With COPD: Results From Replicate Phase 3 Trials","authors":"F. Sciurba, A. Anzueto, T. Rheault, T. Bengtsson, K. Rickard","doi":"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5005","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5005","url":null,"abstract":"","PeriodicalId":332705,"journal":{"name":"C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123692481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in the Enhance-1 Phase 3 Trial of Ensifentrine in COPD Ensifentrine是一种新型的双磷酸二酯酶(PDE) 3和4抑制剂，在Ensifentrine治疗COPD的增强-1期3期试验中，可改善肺功能、症状、生活质量并降低恶化率和风险
C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5006
F. Sciurba, R. Wise, T. Rheault, T. Bengtsson, K. Rickard
{"title":"Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in the Enhance-1 Phase 3 Trial of Ensifentrine in COPD","authors":"F. Sciurba, R. Wise, T. Rheault, T. Bengtsson, K. Rickard","doi":"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5006","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5006","url":null,"abstract":"","PeriodicalId":332705,"journal":{"name":"C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133462115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Improves COPD Symptoms and Quality of Life in the Phase 3 Enhance-1 Trial Ensifentrine，一种新型双磷酸二酯酶(PDE) 3和4抑制剂，在3期增强-1试验中显着改善COPD症状和生活质量
C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5007
F. Sciurba, T. Rheault, T. Bengtsson, K. Rickard
{"title":"Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Improves COPD Symptoms and Quality of Life in the Phase 3 Enhance-1 Trial","authors":"F. Sciurba, T. Rheault, T. Bengtsson, K. Rickard","doi":"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5007","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5007","url":null,"abstract":"","PeriodicalId":332705,"journal":{"name":"C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD","volume":"71 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131812234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, in Moderate and Severe COPD: Symptoms, Quality of Life and Health Status From the Phase 3 Trial Enhance-2 新型双磷酸二酯酶(PDE) 3和4抑制剂Ensifentrine在中度和重度COPD中的应用:来自3期试验的症状、生活质量和健康状况
C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5000
T. Rheault, T. Bengtsson, K. Rickard
{"title":"Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, in Moderate and Severe COPD: Symptoms, Quality of Life and Health Status From the Phase 3 Trial Enhance-2","authors":"T. Rheault, T. Bengtsson, K. Rickard","doi":"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5000","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5000","url":null,"abstract":"","PeriodicalId":332705,"journal":{"name":"C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124058998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Twice-daily, Nebulized Ensifentrine Significantly Improves Lung Function: Sub-group Analysis in the Phase 3 Trial ENHANCE-1 每日两次雾化恩西芬碱可显著改善肺功能:3期临床试验亚组分析
C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5004
T. Siler, T. Rheault, T. Bengtsson, K. Rickard
{"title":"Twice-daily, Nebulized Ensifentrine Significantly Improves Lung Function: Sub-group Analysis in the Phase 3 Trial ENHANCE-1","authors":"T. Siler, T. Rheault, T. Bengtsson, K. Rickard","doi":"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5004","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5004","url":null,"abstract":"","PeriodicalId":332705,"journal":{"name":"C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129927337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ensifentrine, a Dual Inhibitor of PDE3 and PDE4, Reduces the Risk of Exacerbation Regardless of Background Medication Use: A Sub-group Analysis of ENHANCE-2, a Phase 3 Trial Ensifentrine，一种PDE3和PDE4的双重抑制剂，无论背景药物使用如何，都可以降低恶化的风险:一项3期试验ENHANCE-2的亚组分析
C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4999
G.T. Ferguson, T. Rheault, T. Bengtsson, K. Rickard
{"title":"Ensifentrine, a Dual Inhibitor of PDE3 and PDE4, Reduces the Risk of Exacerbation Regardless of Background Medication Use: A Sub-group Analysis of ENHANCE-2, a Phase 3 Trial","authors":"G.T. Ferguson, T. Rheault, T. Bengtsson, K. Rickard","doi":"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4999","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4999","url":null,"abstract":"","PeriodicalId":332705,"journal":{"name":"C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD","volume":"79 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122454719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety Results From Dual PDE3/4 Inhibitor Ensifentrine: Gastrointestinal and Cardiovascular Safety From a 24-week Phase 3 Trial, Enhance-2 双重PDE3/4抑制剂Ensifentrine的安全性结果:来自24周的3期试验的胃肠道和心血管安全性，Enhance-2
C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5003
T. Siler, K. Rickard, T. Bengtsson, T. Rheault
{"title":"Safety Results From Dual PDE3/4 Inhibitor Ensifentrine: Gastrointestinal and Cardiovascular Safety From a 24-week Phase 3 Trial, Enhance-2","authors":"T. Siler, K. Rickard, T. Bengtsson, T. Rheault","doi":"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5003","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5003","url":null,"abstract":"","PeriodicalId":332705,"journal":{"name":"C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129897274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Treatment With Ensifentrine, a Dual PDE3 and PDE4 Inhibitor, Significantly Reduced Exacerbation Rate and Risk in Subjects With COPD: Sub-group Results From the Phase 3 Trial, Enhance-2 Ensifentrine，一种双重PDE3和PDE4抑制剂治疗，显著降低COPD患者的加重率和风险:来自3期试验的亚组结果，Enhance-2
C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4998
A. Anzueto, T. Rheault, T. Bengtsson, K. Rickard
{"title":"Treatment With Ensifentrine, a Dual PDE3 and PDE4 Inhibitor, Significantly Reduced Exacerbation Rate and Risk in Subjects With COPD: Sub-group Results From the Phase 3 Trial, Enhance-2","authors":"A. Anzueto, T. Rheault, T. Bengtsson, K. Rickard","doi":"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4998","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4998","url":null,"abstract":"","PeriodicalId":332705,"journal":{"name":"C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116316892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Reduces Annualized Exacerbations and Delays the Time to First Exacerbation in COPD: Pooled Sub-Group Analyses of Enhance-1 and Enhance-2 Phase 3 Trials Ensifentrine是一种新型的双磷酸二酯酶(PDE) 3和4抑制剂，可显著减少COPD的年化恶化并延迟首次恶化的时间:Enhance-1和Enhance-2 3期试验的合并亚组分析
C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5008
I. Barjaktarevic, T. Rheault, T. Bengtsson, K. Rickard
{"title":"Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Reduces Annualized Exacerbations and Delays the Time to First Exacerbation in COPD: Pooled Sub-Group Analyses of Enhance-1 and Enhance-2 Phase 3 Trials","authors":"I. Barjaktarevic, T. Rheault, T. Bengtsson, K. Rickard","doi":"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5008","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5008","url":null,"abstract":"","PeriodicalId":332705,"journal":{"name":"C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123545727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Oral Treatment With Quercetin Reduces Markers of Inflammation in COPD Patients 口服槲皮素治疗可降低COPD患者炎症标志物
C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5001
S. Patel, N. Marchetti, H. Ganjian, S. Kelsen, G. Criner, U. Sajjan
{"title":"Oral Treatment With Quercetin Reduces Markers of Inflammation in COPD Patients","authors":"S. Patel, N. Marchetti, H. Ganjian, S. Kelsen, G. Criner, U. Sajjan","doi":"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5001","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5001","url":null,"abstract":"","PeriodicalId":332705,"journal":{"name":"C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD","volume":"58 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126273083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信